



ASX ANNOUNCEMENT

10 June 2022

## **CHIMERIC COMPLETES KEY MANUFACTURING MILESTONE SUPPORTING EXPANSION OF CLINICAL PROGRAM**

- Completion of manufacturing and quality release of viral vector for CHM 1101 (CLTX CAR T)
- Viral vector is the backbone of CAR T cell therapy manufacturing, which combined with recent capacity issues worldwide, makes this a critical milestone achieved by Chimeric

Chimeric Therapeutics (ASX:CHM, “Chimeric”), a clinical-stage cell therapy company and an Australian leader in cell therapy, is pleased to announce the completion of manufacturing and quality release for CHM 1101 (CLTX CAR T) viral vector, a key milestone in its development. The viral vector was developed and manufactured at City of Hope, a world-renowned cancer research and treatment organization near Los Angeles.

Chimeric is currently focused on expanding the CHM 1101 (CLTX CAR T) clinical program with new clinical sites for the Phase 1 glioblastoma trial as well as a new Phase 1 clinical basket trial in solid tumours. This broadened clinical development program requires coordinated expansion of Chimeric’s current technical operations.

One of the most challenging and critical components of cell therapy technical operations is the timely manufacturing and release of viral vector. Viral vector is considered the backbone for the manufacture of a CAR T cell therapy as it holds the genetic engineering instructions. A current shortage of vector manufacturing capacity has significantly delayed other cell therapy company development programs, as well as challenging commercial manufacturers.

Given these difficulties this is a critical milestone for Chimeric in supporting the broader Phase 1 clinical program expansion of CHM 1101 (CLTX CAR T).

“This marks a major milestone for advancing the development of CHM 1101,” said Chimeric CEO and Managing Director Jennifer Chow. “Vector supply significantly challenges the cell therapy industry with current backlogs of more than a year to access vector manufacturing. Securing vector for the expansion of our CHM 1101 development program enables us to move forward and is a clear demonstration of the benefit of our experienced cell therapy development team.”

Authorised on behalf of the Chimeric Therapeutics board of directors by Chairman Paul Hopper.

For personal use only



## ABOUT CHIMERIC THERAPEUTICS

Chimeric Therapeutics, a clinical stage cell therapy company and an Australian leader in cell therapy, is focused on bringing the promise of cell therapy to life for more patients with cancer. We believe that cellular therapies have the promise to cure cancer, not just delay disease progression.

To bring that promise to life for more patients, Chimeric's world class team of cell therapy pioneers and experts is focused on the discovery, development, and commercialization of the most innovative and promising cell therapies.

CHM 1101 (CLTX CAR T) is a novel and promising CAR T therapy developed for the treatment of patients with solid tumours. CHM 1101 is currently being studied in a phase 1 clinical trial in recurrent / progressive glioblastoma. Initial positive data has been presented on patients treated in the first two dose levels of the trial. A 2nd CLTX CAR T phase 1 clinical trial is planned to begin in metastatic melanoma with future expansion to additional solid tumours.

CHM 2101 (CDH17 CAR T) is a novel, 3rd generation CDH17 CAR T invented at the world-renowned cell therapy centre, the University of Pennsylvania. Preclinical evidence for CHM 2101 was published in March 2022 in Nature Cancer. CHM 2101 (CDH17 CAR T) is currently in preclinical development with a planned phase 1 clinical trial in neuroendocrine tumours, colorectal, gastroesophageal and gastric cancer.

CHM 0201 (CORE-NK platform) is a clinically validated, off the shelf natural killer (NK) cell platform. Data from the complete phase 1 clinical trial was published in March 2022, demonstrating safety and efficacy in blood cancers and solid tumours. From the CORE-NK platform, Chimeric will initiate development of four new next generation NK and CAR NK assets with plans for phase 1 clinical trials in solid tumours and blood cancers.

Chimeric Therapeutics continues to be actively engaged in further developing its oncology pipeline with new and novel cell therapy assets that will bring the promise of cell therapy to life for more patients with cancer.

## CONTACT

### Investors

Jennifer Chow  
Chief Executive Officer and Managing Director  
Chimeric Therapeutics  
T: + 1 9087238387  
E: [jchow@chimerictherapeutics.com](mailto:jchow@chimerictherapeutics.com)  
W: [www.chimerictherapeutics.com](http://www.chimerictherapeutics.com)

Paul Hopper  
Executive Chairman  
Chimeric Therapeutics  
T: + 61 406 671 515  
E: [paulhopper@lifescienceportfolio.com](mailto:paulhopper@lifescienceportfolio.com)

For personal use only



Media

Matthew Wright

NWR Communications

P: +61 451 896 420

E: [matt@nwrcommunications.com.au](mailto:matt@nwrcommunications.com.au)

For personal use only